|
|||||
|
|
Dual‐Action Cancer Therapy with Targeted Porous Silicon Nanovectors |
|
| Authors: | Ester Sporleder Yasmin Assan Shasha Rao David Warther Clive A Prestidge Jean‐Olivier Durand Nicolas H Voelcker |
| Affiliation: | 1. ARC Centre of Excellence in Convergent Bio‐Nano Science and Technology, Future Industries Institute, University of South Australia, Mawson Lakes, SA, Australia;2. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia;3. Institut Charles Gerhardt Montpellier, UMR‐5253 CNRS‐UM‐ENSCM‐UM1cc, 1701, Montpelliercedex 05, France;4. ARC Centre of Excellence in Convergent Bio‐Nano Science and Technology, Future Industries Institute, University of South Australia, Mawson Lakes, SA, AustraliaPresent address: Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, 381 Royal Parade, Parkville, VIC 3052, Australia |
| Abstract: | There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody‐functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two‐stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity. |
| Keywords: | cancer cytotoxicity drug delivery nanoparticles |